{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:48:55Z","timestamp":1787032135655,"version":"build-2736575974"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND:<\/jats:bold>\n                    Treatment for TB is lengthy and toxic, and new regimens are needed.\n                    <jats:bold>METHODS:<\/jats:bold>\n                    Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6\n months (6Pa\n                    <jats:sub>200<\/jats:sub>\n                    MZ) or 4 months (4Pa\n                    <jats:sub>200<\/jats:sub>\n                    MZ); 100 mg pretomanid daily for 4 months in the same combination (4Pa\n                    <jats:sub>100<\/jats:sub>\n                    MZ); or standard DS-TB treatment for 6 months. The primary outcome was treatment failure or relapse at 12 months post-randomisation. The non-inferiority\n margin for between-group differences was 12.0%. Recruitment was paused following three deaths and not resumed.\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Respectively 4\/47 (8.5%), 11\/57 (19.3%), 14\/52 (26.9%) and 1\/53 (1.9%) DS-TB outcomes were unfavourable in patients on 6Pa\n                    <jats:sub>200<\/jats:sub>\n                    MZ, 4Pa\n                    <jats:sub>200<\/jats:sub>\n                    MZ,\n 4Pa\n                    <jats:sub>100<\/jats:sub>\n                    MZ and controls. There was a 6.6% (95% CI \u20132.2% to 15.4%) difference per protocol and 9.9% (95%CI \u20134.1% to 23.9%) modified intention-to-treat difference in unfavourable responses between the control and 6Pa\n                    <jats:sub>200<\/jats:sub>\n                    MZ arms. Grade 3+ adverse events affected\n 68\/203 (33.5%) receiving experimental regimens, and 19\/68 (27.9%) on control. Ten of 203 (4.9%) participants on experimental arms and 2\/68 (2.9%) controls died.\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    PaMZ regimens did not achieve non-inferiority in this under-powered trial. An ongoing evaluation of PMD remains\n a priority.\n                  <\/jats:p>","DOI":"10.5588\/ijtld.20.0513","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:30:32Z","timestamp":1616632232000},"page":"305-314","source":"Crossref","is-referenced-by-count":61,"title":["A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB"],"prefix":"10.5588","volume":"25","author":[{"given":"C. D.","family":"Tweed","sequence":"first","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. H.","family":"Wills","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Crook","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Amukoye","sequence":"additional","affiliation":[{"name":"Centre for Respiratory Disease Research, Kenya Medical Research Institute (KEMRI), Kenyatta National Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Balanag","sequence":"additional","affiliation":[{"name":"Lung Center of the Philippines, National Centre for Pulmonary Research, Quezon City, The Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Y.L.","family":"Ban","sequence":"additional","affiliation":[{"name":"Pusat Perubatan Universiti Kebangsaan, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.C.","family":"Bateson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Microbiology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Betteridge","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Brumskine","sequence":"additional","affiliation":[{"name":"Aurum Institute, Rustenburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Caoili","sequence":"additional","affiliation":[{"name":"Tropical Disease Foundation, Makati Medical Centre, Makati City, Phillippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cevik","sequence":"additional","affiliation":[{"name":"Medical School, University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Conradie","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand, Clinical HIV Research Unit, Johannesburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dawson","sequence":"additional","affiliation":[{"name":"University of Cape Town Lung Institute, Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"del Parigi","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diacon","sequence":"additional","affiliation":[{"name":"TASK Applied Science, Bellville, South Africa & Division of Physiology, Department of Medical Biochemistry, University of Stellenbosch, Tygerberg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Everitt","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Fabiane","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Centre for Clinical Microbiology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Ismail","sequence":"additional","affiliation":[{"name":"Universiti Teknologi MARA, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lalloo","sequence":"additional","affiliation":[{"name":"Enhancing Care Foundation, Durban International Clinical Research Site, Wentworth Hospital, Durban"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lombard","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Louw","sequence":"additional","affiliation":[{"name":"Madibeng Centre for Research, Brits, & Department of Family Medicine, University of Pretoria, Pretoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Malahleha","sequence":"additional","affiliation":[{"name":"Setshaba Research Centre, Soshanguve, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D.","family":"McHugh","sequence":"additional","affiliation":[{"name":"Centre for Clinical Microbiology, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Mendel","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mhimbira","sequence":"additional","affiliation":[{"name":"Ifakara Health Institute (IHI), Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. N.","family":"Moodliar","sequence":"additional","affiliation":[{"name":"THINK (Tuberculosis and HIV Investigative Network), Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Nduba","sequence":"additional","affiliation":[{"name":"KEMRI, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Nunn","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London (UCL), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sabi","sequence":"additional","affiliation":[{"name":"Mbeya Medical Research Center, National Institute for Medical Research, Mbeya, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Sebe","sequence":"additional","affiliation":[{"name":"The Aurum Institute, Tembisa Clinical Research Centre, Tembisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A. P.","family":"Selepe","sequence":"additional","affiliation":[{"name":"The Aurum Institute, Klerksdorp, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Staples","sequence":"additional","affiliation":[{"name":"THINK (Tuberculosis and HIV Investigative Network), Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Swindells","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"van Niekerk","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, Pretoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Variava","sequence":"additional","affiliation":[{"name":"Klerksdorp Tshepong Hospital, Klerksdorp, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Spigelman","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Medical School, University of St Andrews, St Andrews, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2021\/00000025\/00000004\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:48:25Z","timestamp":1625186905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.20.0513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"alternative-id":["1027-3719(20210401)25:4L.305;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.20.0513","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}